Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5% – Should You Buy?

by · The Cerbat Gem

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s share price traded up 3.5% during mid-day trading on Thursday . The company traded as high as $124.66 and last traded at $122.10. 370,039 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 1,267,738 shares. The stock had previously closed at $117.99.

Analyst Ratings Changes

A number of brokerages recently commented on SRPT. Evercore ISI upgraded shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and lowered their target price for the stock from $185.00 to $179.00 in a research note on Thursday, August 8th. Raymond James reissued an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday. Barclays lowered their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Morgan Stanley restated an “overweight” rating and set a $165.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, June 21st. Finally, Bank of America increased their target price on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a research report on Friday, June 21st. Two investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $185.47.

Get Our Latest Research Report on SRPT

Sarepta Therapeutics Stock Up 2.3 %

The firm has a market capitalization of $11.41 billion, a PE ratio of 1,068.64 and a beta of 0.82. The firm’s 50-day moving average is $131.02 and its 200 day moving average is $132.55. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. During the same quarter in the prior year, the company earned ($0.27) EPS. Sarepta Therapeutics’s revenue was up 38.9% on a year-over-year basis. As a group, research analysts forecast that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The shares were bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors have recently bought and sold shares of the business. Riggs Asset Managment Co. Inc. boosted its position in Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares during the period. GAMMA Investing LLC raised its holdings in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 87 shares during the period. EP Wealth Advisors LLC boosted its holdings in Sarepta Therapeutics by 2.1% in the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after acquiring an additional 103 shares during the period. Cambridge Investment Research Advisors Inc. raised its stake in shares of Sarepta Therapeutics by 1.9% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 120 shares during the period. Finally, Innealta Capital LLC acquired a new position in shares of Sarepta Therapeutics during the second quarter worth $31,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Read More